

Prevalence of *Helicobacter pylori vacA, cagA, cagE1, cagE2, dupA and oipA* Genotypes in Patients With Gastrointestinal Diseases

Hossein Masoumi Asl¹, Ali Badamchi², Shima Javadinia³, Siamak Khaleghi⁴, Leila Tehraninia², Samaneh Saedi⁵, Azardokht Tabatabaei¹

¹ Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran

² Children's Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran

³ Department of Lung, Firoozabadi Hospital, Iran University of Medical Sciences, Tehran, Iran

⁴ Department of Gastroenterology, Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, Iran

⁵ Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran

Received: 04 Jan. 2020; Accepted: 11 Jun. 2020

Abstract- *Helicobacter pylori* (*H. pylori*) is a bacterium that resides in the human stomach, which is associated with gastroduodenal diseases. We investigate the prevalence of *cagA*, *vacA*, *oipA*, *cagE1*, *cagE2* and *dupA* genotypes in *H. pylori* isolated from patients with Gastric ulcer, duodenal ulcer, and Gastric Cancer. Collected 74 samples from the Gastroenterology Unit of the Rasool Akram Hospital were included in this study. Gastric disorders were identified by endoscopy. Gastric cancer was further confirmed by histopathology. *H. pylori* were detected by the urease test. Subsequently, DNA was extracted from gastric tissue of the subjects with the CLO-test yielded positive results. In general, 74 patients with a mean age of 53.45 years (Range 22 to 86-year-old), including 45 men and 29 women, were studied. Among 74 *H. pylori*-positive patients, 70 (94.5%) patients were positive for the *cagA* gene. About 95.8% (23/24) of the patients with gastric carcinoma were *dupA* positive and *VacA* gene (91.8%). The *oipA* genotype was detected in 71 (96%) of *H. pylori* positive samples. This gene was more common in patients with gastritis rather than cancer group. Also, 97.2% of 74 *H. pylori* isolates were *cagE2*-positive. In 25 patients with PUD, the occurrence percent of *cagA*+/*VacA*+, *cagA*+/*Vac*-, *cagA*-/*VacA*+ and *cagA*-/*VaxA*- genotypes were found 80%, 12%, 4.2% and 4.2% respectively. The results of the present study suggest that a high prevalence of virulent factors could contribute to the risk of developing gastroduodenal diseases.

© 2020 Tehran University of Medical Sciences. All rights reserved.

Acta Med Iran 2020;58(7):310-317.

Keywords: *Helicobacter pylori*; Vacuolating cytotoxin gene A (*vacA*); Cytotoxin-associated gene A (*cagA*); Cytotoxin-associated gene E1 (*cagE1*); Cytotoxin-associated gene E2 (*cagE2*), Duodenal ulcer promoting gene A (*dupA*)

Introduction

Helicobacter pylori (*H. pylori*) is a human-specific pathogen that infects approximately 50% of the population worldwide. The way of infection for *H. pylori* is forcefully based on person-to-person transmission and fecal-oral and oral-oral routes (1).

The infection implicates several medical conditions responsible for 90% of the gastric cancer cases, such as chronic gastritis, gastric ulcers, duodenal ulcers, gastric cancer, and peptic ulcer disease (2). The prevalence rates of infection vary greatly in the world. In developed

countries, prevalence rates of infection among children have been shown to range from 1.8% up to 65%, and the epidemic range of infection in developing countries is higher than in developed countries and up to 90% (3,4). In Iran, we observe different prevalence rates of *H. pylori* infection (5).

A unique trait infection is a permanence, which causes prolonged active inflammation, including the influx of neutrophils. Flagella and urease activity of *H. pylori* cause colonization in the gastric mucosa (6). The adhesive interaction of *H. pylori* and cellular receptors help the gastric mucosa infection, which is caused by

Corresponding Author: A. Tabatabaei

Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran
Tel: +98 21 66516049, Fax: +98 21 66516049, E-mail address: azardokht_tabatabaei@yahoo.com

tissue damage by the secretion of virulence factors (such as *vacA*, *cagA*, *dupA*, and *oipA* genes). Analysis of genomic variation is useful for epidemiological studies in *H.pylori*. Many virulence-associated genes have an essential role in infection, such as vacuolating cytotoxin gene A (*vacA*), cytotoxin-associated gene A (*cagA*), and duodenal ulcer promoting gene A (*dupA*) (7). The *vacA* gene encodes the vacuolating cytotoxin A, produced by approximately 50% of the *H.pylori* strains (8). In human *vacA*, increase the risk of developing gastric cancer by inhibition of T-cell proliferation and activation of proinflammatory response (9). *CagA* is produced by approximately 50 to 60% of the *H.pylori* strains. The attendance of *cagA* correlated with duodenal ulceration and gastric cancer (9). *CagA* is part of Pathogenicity Island (*cag*-PAI) that is related to the virulence and pathogenicity of the *H.pylori* strain (9,10). *cagE* is another *cag*-PAI gene. This gene is associated with more virulent *H.pylori* strains; several studies have described an association between *cagE* and gastritis, duodenal ulcer, and peptic ulcer diseases (11).

The first disease-specific virulence factor is *dupA* because of its ability to enhance the risk for gastric. However, infections with *H.pylori dupA*-negative strains can increase the risk for duodenal ulcer, but it reduces the chance of occurrence for gastric (12). Studies show an association between the *dupA* gene and high IL-8

production from gastric epithelial cells that causing dominant gastritis (13). Outer membrane inflammatory protein A, The outer inflammatory protein (OipA), is an outer membrane protein-specific *H. pylori*. This protein has special functions, including adhesion and pH regulation (13). OipA is a major virulence factor of *H.pylori*, which is associated with peptic ulcer and enhanced inflammation by increased interleukin-8 secretion (14).

This study aimed to investigate the frequency of *cagA*, *vacA*, *oipA*, *cagE1*, *cagE2* and *dupA* genotypes in *H.pylori* isolated from patients with Gastric ulcer, duodenal ulcer, and Gastric Cancer.

Materials and Methods

Patients

Sampling was performed from 74 patients with gastroduodenal diseases referred to Rasool Akram Hospital in Tehran from March to September. These patients underwent standard gastric endoscopy. At the time of sampling, patients had not received any proton pump inhibitor drugs or antibiotics for at least two weeks before. The clinical features of the patients recruited are presented in Table 1.

Table 1. Demographic and clinical characteristics of patients

	Male (N=45)	Female (N=29)	Total (N=74)	
Age (mean±SD)	56±17.8	48±14.5	53.45±15.7	
Result of endoscopy	Gastric ulcer	10(22.22%)	15(51.4%)	25(33.8%)
	Duodenal ulcer	15(33.33%)	10(34.5%)	25(33.8%)
	gastric Cancer	20(44.45%)	4(13.8%)	24(32.4%)

Biopsy extract

Three gastric biopsies from the gastric antrum or body (1 sample for histological examination, 1 sample for CLO test, and 1 for PCR) were obtained from patients after obtaining their informed consent. This protocol was approved by the Rasool Akram Hospital Ethics Committee. *H.pylori* infection was evaluated by Urease Test, histology as well as polymerase chain reaction (PCR). Gastric ulcer (GU), duodenal ulcer (DU), and Gastric Cancer (GC) diagnosis were identified by endoscopy, and gastric cancer diagnosis was further confirmed by histopathology. Gastritis was defined as histological gastritis in the absence of peptic ulcer or gastric malignancy. All endoscopy and histology results evaluated and confirmed by a specialist (15).

The urease test (CLO test)

One biopsy extract samples from the antrum were used for the detection of *H.pylori* by the urease test. A fragment is placed in a tube containing urea indole to detect urease activity, which shows the presence of the bacteria in the biopsy. The positive result is interpreted by the color change of urea-indole from orange to pink or red after incubation at 37° C for 24 h.

DNA extraction and *H.pylori* genotyping

H.pylori DNA was extracted from gastric tissue in patients with CLO-test yielded positive results. DNA was extracted using the QIAamp DNA Mini Kit (QIAGEN, USA) according to the manufacturer's instructions in Table 2.

Data analyses

All results are expressed as frequency and percentage as appropriate. Fisher's exact test or the Chi-square test was used for analyzing categorical data. A *P* of less than

0.05 was considered statistically significant. The data analysis was performed using the SPSS software version 24.

Table 2. primers used in PCRs

Gene	Sequence (5' -3')	Temperature annealing
<i>CagA</i>	CTAACGAAACTATTGACC GTTATTTTTGGCTGTTAGCTTG	45
<i>VacA</i>	CAATCTGTCCAATCAAGCGAG GCGTCAAAATAATTCCAAGG	47
<i>dupA</i>	TGGTTTCTACTGACAGAGCGC AACACGCTGACAGGACAATCTCCC	56
<i>OipA</i>	CCATGAAAAAAGCTCTCTTAC GCCCTTTTACCCTTCGTTCAA	43
<i>cagE1</i>	AGACATGCAAAAAGGTAT CAATCTAGTGGGGTGGTA	48
<i>cagE2</i>	TGCTGATACGATTAGAGA TAGTCCCTTAGTGATGAT	48

Results

Seventy-four patients with a mean age of 53.45 years (Range 22 to 86 years old), including 45 men and 29 women, were studied (Table 1).

Relationship between *H.pylori* virulence factors and clinical outcomes

Among 74 *H.pylori* positive patients, 70 patients were

positive for the *cagA* gene (94.5%) (Table 3). The majority of patients with *cagA* genotype had Gastric disorder (23/74, 31 %), Peptic ulcer was found only in 32.4 % (24/74) of patients and percent of patients with Gastric cancer was (23/74, 31 %), but differences could not reach statistically significant (Table 3). Almost all patients were positive for the *VacA* gene (91.8%); there was no relationship between the *vacA* gene and clinical outcomes (Table 4).

Table 3. A variety of gastrointestinal diseases, Virulence Factors of *H.pylori* and Clinical Outcomes (*P*<0.05 is considered significant)

Genotype	Gastric ulcer 25(%)	Duodenal ulcer 25(%)	Gastric cancer 24(%)	<i>P</i>
<i>CagA</i> ⁻	2(2.7%)	1 (1.3%)	1 (1.3%)	0.7
<i>CagA</i> ⁺	23 (31%)	24 (32.4%)	23 (31%)	
<i>VacA</i> ⁻	3 (4%)	2 (2.7%)	1 (1.3%)	0.6
<i>VacA</i> ⁺	22 (29.7%)	23 (31%)	23 (31%)	
<i>dupA</i> ⁻	1 (1.3%)	1 (1.3%)	1 (1.3%)	0.9
<i>dupA</i> ⁺	24 (32.4%)	24 (32.4%)	23 (31%)	
<i>OipA</i> ⁻	1 (1.3%)	1 (1.3%)	1 (1.3%)	0.9
<i>OipA</i> ⁺	24 (32.4%)	24 (32.4%)	23 (31%)	
<i>CagE1</i> ⁻	0	0	0	0.9
<i>CagE1</i> ⁺	25 (33.8%)	25 (100%)	24 (100%)	
<i>CagE2</i> ⁻	1 (1.3%)	1(1.3%)	0	0.9
<i>CagE2</i> ⁺	24 (32.4%)	24 (32.4%)	24 (32.4%)	

(*P*<0.05 is considered significant)

Table 4. Relationship between two genes; *vacA* gene with *cagA* gene

Genotype/N (%)	<i>cagA</i> gene		<i>P</i>	
	Positive 70	Negative 4		
<i>vacA</i> gene	Positive 68(%) Negative 6(%)	65(95.6%) 5(83.3%)	3(4.4%) 1(16.7%)	0.8

P< 0.05 is considered significant

About 96 % (24/25) of *H.pylori* strains of patients

with gastritis, 96 % (24/25) from those with duodenal

ulcer, and 95.8% (23/24) of the patients with gastric carcinoma were *dupA* positive (Table 3). There was no significant difference in the prevalence of *dupA* and *CagA* genotypes between studied groups, suggesting an association with the development of disease in this population (Table 5).

The *oipA* genotype was detected in 71 (96%) of *H. pylori* positive samples. This gene was more common in patients with gastritis rather than cancer group (Table 3).

In total, 100% of 74 collected *H. pylori* isolates were *cagE1*-positive (Table 3). There was no relationship between *cagA* and *cagE* genotypes status. Of the, 70 isolates of 74 *cagE1*-positive isolates were *cagA* positive, and 4(5.4%) isolates were *cagA*-negative (not significant) (Table 6).

In total, 97.2% of 74 *H. pylori* isolates were *cagE2*-

positive. There was no relationship between *cagA* and *cagE2* genotype. Of the 72 isolates that were *cagE2*-positive, 70 isolates were *cagA* positive, and two isolates were *cagA*-negative (not significant) of *cagA*-negative isolates, two isolates that were *cagE2*-positive (table 7).

According to Table7, In 25 patients with PUD, the occurrence percent of *cagA*+/*VacA*+, *cagA*+/*Vac*-, *cagA*-/*VacA*+ and *cagA*-/*VaxA*- genotypes were found 80%, 12%, 4.2% and 4.2 respectively. In 22 patients with duodenal ulcers, the occurrence percent of desired genotypes were 88%, 8%, 0%, and 4.2 %, respectively. Occurrence percent of *cagA*+/*VacA*+, *cagA*+/*Vac*-, *cagA*-/*VacA*+ and *cagA*-/*VaxA* genotypes in patients with cancer were 87.5%, 4.2%, 4.2% and 0% respectively. As shown, the difference between the occurrence percent of different genotypes of different diseases was significant (Table 8).

Table 5. Relationship between two genes; *dupA* gene with *cagA* gene

Genotype/N (%)	cagA gene		P
	Positive 70	Negative 4	
<i>dupA</i> gene	Positive 72(%)	69(95.8%)	0.8
	Negative 2(%)	1(50%)	

P<0.05 is considered significant

Table 6. Relationship between two genes; *cagE1* gene with *cagA* gene.

Genotype/N (%)	cagA gene		P
	Positive 70	Negative 4	
<i>CagE1</i> gene	Positive 74(%)	70(94.6%)	0.9
	Negative 0(%)	0	

P<0.05 is considered significant

Table 7. Relationship between two genes; *cagE2* gene with *cagA* gene

Genotype/N (%)	cagA gene		P
	Positive 70	Negative 4	
<i>CagE2</i> gene	Positive 72(%)	70(97.2%)	0.8
	Negative 2(%)	0	

P<0.05 is considered significant

Table 8. Frequency of selected genes in *H. pylori* strains

Genotypes combinations	PUD (Gastric ulcer) N (%)	Duodenal ulcer N (%)	cancer N (%)	P
<i>cagA</i> +/ <i>VacA</i> +	20(80)	22(88)	21(87.5)	0.01
<i>cagA</i> +/ <i>VacA</i> -	3(12)	2(8)	1(4.2)	
<i>cagA</i> -/ <i>VacA</i> +	1(4.2)	0	1(4.2)	
<i>cagA</i> -/ <i>VacA</i> -	1(4.2)	1(4.2)	0	

P<0.05 is considered significant

Discussion

H. pylori infection is prevalent worldwide. *H. pylori* is

one of the most genetically diverse bacterial species which may be involved in the complex variety of gastroduodenal diseases in infected patients all over the

world (16). In general, the prevalence is high in developing countries, and the infection is acquired at a young age. The outbreak of *H.pylori* infection is not lower in developed countries than in developing countries. For example, prevalence infection has reported more than 80% in Japan, Turkey, and Pakistan (17,18,19).

Latifi *et al.*, Provide evidence that the frequency of gastrointestinal ulcer and gastric cancer is largely influenced by geographical conditions and ethnic groups that reflects historical interactions with external populations in Iran (16). The prevalence of this bacterium has been found 60-90%, indicating that Iran is a highly risky region for *H. pylori* infection. The prevalence of infection of our studied subjects was 82 %, indicating that our findings are consistent with previous reports in Iran (20,21,16).

In this study, the prevalence of *H. pylori* virulence factors from Rasool Akram Hospital in Tehran was tested and evaluated. It is estimated that 69% of the Iranian population currently suffers from *H. pylori* infection. The dominant genotypes in this study were the *cagE1*, followed by the *cagE2, cagA, dupA, oipA* (22) we show that these genotype variations modify the Clinical manifestations in *H. pylori*-infected patients. According to the results of studies on adults that identified an association between infection with *cagA+* strains and peptic ulcer disease. However, subsequent studies have provided more inconsistent results. The current study demonstrated that the majority (94.5%) of the strains isolated from Iranian patients were *cagA+* positive. Salih *et al.*, (23), found that *H.pylori* infection is highly associated with DU (95.7%) and GU (87%). Differences in the applied methods of analysis might be the reason for such controversy. The *cagA* gene was reported in 73%, 55%, and 55% of *H. pylori* strains isolated from patients with NUD, PUD, and GC, respectively (24). The prevalence of *cagA+* *H.pylori* differed from one geographic region to another, e.g., 97% in Korea (25), 90% in China (26), and 92% in Iran (27).

The researcher's view about the correlation between *vacA* genotypes and gastric diseases was different. For example, in Iran, Safavi *et al.*, found no correlation between them (28), whereas Molaei *et al.*, found that the *s1a* allele was associated with more severe inflammation (20). In Iran and Cuban strain, no association had been found (29,30).

About 94.5% of all isolates were *cagA+* by PCR, which is in accord with the results of other studies from Europe (31). The majority of the patients with PUD (84%) were infected with *cagA+* strains in contrast to strains that isolated from patients with gastritis only, in

whom 67% of the *H. pylori* strains were *cagA+* (31). *dupA* was described as *H. pylori* virulence marker linked with an increased risk for duodenal ulcer and decreased the risk for gastric carcinoma in Japan and Cuban.

In study Kobayashi (19) *et al.*, all samples from an infant with and without duodenal ulcer were *dupA+*. Among the strains isolated from adults with gastritis (92.36%), duodenal ulcer (87.30%, $P=0.30$), and gastric cancer (87.65%, $P=0.31$) with *dupA* association were not observed. all samples from adults with and without duodenal ulcer were *dupA+*. in contrast to the results of Lu *et al.*, (2005), *dupA* was not associated with duodenal ulcer and gastric carcinoma in our population (12).

Prevalence *dupA* gene in this study, 92.36% of *H. pylori* strains from adults with gastritis, 87.30% from those with duodenal ulcer, and 87.65% from the patients with gastric cancer were *dupA* positive. Lack of association between *Helicobacter pylori* infection with *dupA+* strains and gastroduodenal diseases in Brazilian patients is shown. Association between *dupA+* and duodenal ulcers was not observed in patients. Also, the presence of *dupA+* was not associated with gastric cancer (32).

These discordant results may be explained by variations among strains isolated from different continents or ethnic groups. Since *H.pylori* has probably infected human beings since their origins, genetic drift may have happened during geographic isolation resulting in multiple populations and subpopulations that mirror ancient human colonization (33). Besides, DNA loss and rearrangement in the plasticity region are the rules, leading to diversity in gene content that may contribute to bacterial adaptation to the genetically different members of diverse ethnic groups in the human population (33).

Lu *et al.*, reported that *dupA* is associated with an increased risk for DU, and protection against gastric atrophy and GC in Japan (12). In contrast, our results showed that *dupA*-positive *H.pylori* was detected not only in GU and DU patients (1/24) but also in GC patients (1/23), with no significant difference between these groups. The reason for this discrepancy is not clear, though it may be due to the limited number of subjects that were examined in the present study. Because of a shortage of patient's number, the present study should be recognized as a preliminary study. However, this study has presented further support for *dupA* as a negative marker of GC, Compliant with the study of Lu *et al.*, (12). In this study, 96% of isolated strains contain an *oipA* gene, which is following the previous study that showed the *oipA* prevalence varies from 33% to 71% in the Iranian population based on the different ethnic

backgrounds (34). In opposite to previous studies, that identified the *oipA* gene incidence 45.9% and 30% for their studied *H.pylori* isolates (35,36).

Probably an epigenetic influence on this locus may intensify on phase variation of *oipA*. In the majority of studies, the *oipA* gene was present in most strains. In contrast, there were many *oipA* negatives in Shao *et al.*, study. They declared that there is no correlation between the *oipA* gene and gastric diseases (37). All over, the existence of the *oipA* gene and clinical outcomes are still unknown. In this study, there was not a statistically significant correlation between the lack of *oipA* gene and the presence of *dupA* in isolated strains. According to the results, there was no correlation between the *dupA* gene presence, gastric cancer, and *oipA* gene. However, no significant correlations were found between the virulence factors in the gastric cancer group.

The importance of *cagE* gene presence can be observed by its high frequency in gastric cancer in India (100%) and Thailand (93.8%) populations (38,39). In addition, the *cagE* gene has proposed a good character for the integrity of *cag*-PAI than *cagA* (40). Therefore, our data confirm that the *cagA* gene is a good single marker of the pathogenicity of the island. However, it is suggested the use of both as markers for *cag*-PAI existence and also for the pathological importance of these genes.

Taken together, our results suggest that the high prevalence of virulent factors help to the risk of extending gastroduodenal diseases. We assume that the more virulence combination may be a trigger for chronic gastritis and a pioneer lesion of gastric cancer. This is the first study to disclose a high prevalence of the *oipA* gene in *H.pylori* isolates in Iran. Furthermore, this study discloses a high prevalence of the combination of *cagA*, *vacA*, *dupA*, and *oipA* genes.

Acknowledgments

The authors acknowledge the research center of pediatric infectious diseases for their financial support grants.

References

- Boehnke KF, Eaton KA, Valdivieso M, Baker LH, Xi C. Animal Model Reveals Potential Waterborne Transmission of *Helicobacter pylori* Infection. *Helicobacter* 2015;20:326-33.
- Sayehmiri F, Kiani F, Sayehmiri K, Soroush S, Asadollahi K, Alikhani MY, et al. Prevalence of *cagA* and *vacA* among *Helicobacter pylori*-infected patients in Iran: a systematic review and meta-analysis. *J Infect Dev Ctries* 2015;9:686-96.
- Okuda M, Osaki T, Lin Y, Yonezawa H, Maekawa K, Kamiya S, et al. Low Prevalence and Incidence of *Helicobacter pylori* Infection in Children: A Population-Based Study in Japan. *Helicobacter* 2015;20:133-8.
- Sallas ML, Melchiades JL, Zabaglia LM, Moreno J. Prevalence of *Helicobacter pylori vacA, cagA, dupA* and *oipA* genotypes in patients with Gastric Disease. *Adv Microbiol* 2017;7:1-9.
- Moosazadeh M, Lankarani KB, Afshari M. Meta-analysis of the prevalence of *Helicobacter pylori* infection among children and adults of Iran. *Int J Prev Med* 2016;7:48.
- Eaton KA, Krakowka S. Effect of gastric pH on urease-dependent colonization of gnotobiotic piglets by *Helicobacter pylori*. *Infect Immun* 1994;62:3604-7.
- Erzin Y, Koksall V, Altun S, Dobrucali A, Aslan M, Erdamar S, Dirican A, et al. Prevalence of *Helicobacter pylori vacA, cagA, cagE, iceA, babA2* genotypes and correlation with clinical outcome in Turkish patients with dyspepsia. *Helicobacter* 2006;11:574-80.
- Akeel M, Shehata A, Elhafey A, Elmakki E, Aboshouk T, Ageely H. et al. *Helicobacter pylori vacA, cagA* and *iceA* genotypes in dyspeptic patients from southwestern region, Saudi Arabia: distribution and association with clinical outcomes and histopathological changes. *BMC gastroenterol* 2019;19:16.
- Yamaoka Y, Graham DY. *Helicobacter pylori* virulence and cancer pathogenesis. *Future Oncol* 2014;10:1487-500.
- Shiota S, Suzuki R, Yamaoka Y. The significance of virulence factors in *Helicobacter pylori*. *J Dig Dis* 2013;14:341-9.
- Lima VP, de Lima MAP, Ferreira MVP, Barros MAP, Rabenhorst SHB. The relationship between *Helicobacter pylori* genes *cagE* and *virB11* and gastric cancer. *Int J Infect Dis* 2010;14:e613-e7.
- Lu H, Hsu P-I, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of *Helicobacter pylori*. *Gastroenterology* 2005;128:833-48.
- Argent RH, Burette A, Miendje Deyi VY, Atherton JC. The presence of *dupA* in *Helicobacter pylori* is not significantly associated with duodenal ulceration in Belgium, South Africa, China, or North America. *Clin Infect Dis* 2007;45:1204-6.
- Fazeli Z, Alebouyeh M, Tavirani MR, Azimirad M, Yadegar A. *Helicobacter pylori CagA* induced interleukin-8 secretion in gastric epithelial cells. *Gastroenterology and hepatol bed bench* 2016;9:S42-6.
- Vaziri F, Peerayeh SN, Alebouyeh M, Molaei M, Maghsoudi N, Zali MR. Determination of *Helicobacter*

- pylori* CagA EPIYA types in Iranian isolates with different gastroduodenal disorders. *Infect Genet Evol* 2013;17:101-5.
16. Latifi-Navid S, Ghorashi SA, Siavoshi F, Linz B, Massarrat S, Kheday T, et al. Ethnic and geographic differentiation of *Helicobacter pylori* within Iran. *PLoS one* 2010;5:e9645.
 17. Nagiyev T, Yula E, Abayli B, Koksai F. Prevalence and genotypes of *Helicobacter pylori* in gastric biopsy specimens from patients with gastroduodenal pathologies in the Cukurova region of Turkey. *J Clin Microbiol* 2009;47:4150-3.
 18. Ahmad T, Sohail K, Rizwan M, Mukhtar M, Bilal R, Khanum A. Prevalence of *Helicobacter pylori* pathogenicity-associated *cagA* and *vacA* genotypes among Pakistani dyspeptic patients. *FEMS Immunol Med Microbiol* 2009;55:34-8.
 19. Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi SI, et al. Changing antimicrobial susceptibility epidemiology of *Helicobacter pylori* strains in Japan between 2002 and 2005. *J clin microbiol* 2007;45:4006-10.
 20. Molaei M, Foroughi F, Mashayekhi R, Haghazali M, Zojaji H, Jafari F, et al. CagA status and VacA subtypes of *Helicobacter pylori* in relation to histopathologic findings in Iranian population. *Indian J Pathol Microbiol* 2010;53:24.
 21. Jafari F, Shokrzadeh L, Dabiri H, Baghaei K, Yamaoka Y, Zojaji H, et al. *vacA* genotypes of *Helicobacter pylori* in relation to *cagA* status and clinical outcomes in Iranian populations. *Jpn J Infect Dis* 2008;61:290-3.
 22. Alvandi AH, Abiri R, Ahmadi-Jouybari T, Souri N. Genetic Diversity of *Helicobacter pylori* Strains Isolated from Patients with Gastroduodenal Diseases Using Multilocus Sequence Typing in Kermanshah. *Jundishapur J Microbiol* 2019;12:e81052.
 23. Salih BA, Abasiyanik MF, Bayyurt N, Sander E. *H. pylori* infection and other risk factors associated with peptic ulcers in Turkish patients: A retrospective study. *World J Gastroenterol* 2007;13:3245-8.
 24. Dabiri H, Maleknejad P, Yamaoka Y, Feizabadi MM, Jafari F, Rezadehbashi M, et al. Distribution of *Helicobacter pylori cagA, cagE, oipA* and *vacA* in different major ethnic groups in Tehran, Iran. *J Gastroenterol Hepatol* 2009;24:1380-6.
 25. Kim JM, Kim JS, Kim N, Jung HC, Song IS. Distribution of fluoroquinolone MICs in *Helicobacter pylori* strains from Korean patients. *J Antimicrob Chemother* 2005;56:965-7.
 26. Hu Y, Zhu Y, Lu N-h. Primary antibiotic resistance of *Helicobacter pylori* in China. *Dig Dis Sci* 2017;62:1146-54.
 27. Nahaei MR, Sharifi Y, Akhi MT, Asgharzadeh M, Nahaei M, Fatahi E. *Helicobacter pylori caga* and *vaca* genotypes and their relationships to peptic ulcer disease and non-ulcer dyspepsia. *Res J Microbiol* 2008;3:386-94.
 28. Safavi M, Sabourian R, Foroumadi A. Treatment of *Helicobacter pylori* infection: current and future insights. *World J Clin Cases* 2016;4:5-19.
 29. Izadi M, Fazel M, Sharubandi SH, Saadat SH, Farahani MM, Nasserli MH, et al. *Helicobacter* species in the atherosclerotic plaques of patients with coronary artery disease. *Cardiovasc Pathol* 2012;21:307-11.
 30. Torres LE, Melián K, Moreno A, Alonso J, Sabatier CA, Hernández M, et al. Prevalence of *vacA, cagA* and *babA2* genes in Cuban *Helicobacter pylori* isolates. *World J Gastroenterol* 2009;15:204-210.
 31. Khayat A, Soweid A, Kattar M, Tawil A, Gold B, Matar G. Prevalence and clinical relevance of *Helicobacter pylori cagA* and *vacA* genes in Lebanese patients with gastritis and peptic ulcer disease. *J Infect Dev Ctries* 2007;1:55-61.
 32. Gomes LI, Rocha GA, Rocha AM, Soares TF, Oliveira CA, Bittencourt PF, et al. Lack of association between *Helicobacter pylori* infection with *dupA*-positive strains and gastroduodenal diseases in Brazilian patients. *Int J Med Microbiol* 2008;298:223-30.
 33. Gressmann H, Linz B, Ghai R, Pleissner KP, Schlapbach R, Yamaoka Y, et al. Gain and loss of multiple genes during the evolution of *Helicobacter pylori*. *PLoS genet* 2005;1:e43.
 34. Douraghi M, Mohammadi M, Oghalaie A, Abdirad A, Mohagheghi MA, Hosseini ME, et al. *dupA* as a risk determinant in *Helicobacter pylori* infection. *J med microbiol* 2008;57:554-62.
 35. Yamaoka Y, Kikuchi S, El-Zimaity HM, Gutierrez O, Osato MS, Graham DY. Importance of *Helicobacter pylori oipA* in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. *Gastroenterology* 2002;123:414-24.
 36. Kudo T, Nurgalieva ZZ, Conner ME, Crawford S, Odenbreit S, Haas R, et al. Correlation between *Helicobacter pylori OipA* protein expression and *oipA* gene switch status. *J Clin Microbiol* 2004;42:2279-81.
 37. Shao S-H, Wang H, Chai S-G, Liu L-M. Research progress on *Helicobacter pylori* outer membrane protein. *World J Gastroenterol* 2005;11:3011-3.
 38. Chomvarin C, Namwat W, Chaicumpar K, Mairiang P, Sangchan A, Sripa B, et al. Prevalence of *Helicobacter pylori vacA, cagA, cagE, iceA* and *babA2* genotypes in Thai dyspeptic patients. *Int J Infect Dis* 2008;12:30-6.
 39. Ali M, Khan AA, Tiwari SK, Ahmed N, Rao LV, Habibullah C. Association between *cag*-pathogenicity island in *Helicobacter pylori* isolates from peptic ulcer,

gastric carcinoma, and non-ulcer dyspepsia subjects with histological changes. *World J Gastroenterol* 2005;11:6815-22.

40. Módena JL, Acrani GO, Micas AF, Castro MD, Silveira WD, Módena JL, et al. Correlation between *Helicobacter pylori* infection, gastric diseases and life habits among patients treated at a university hospital in Southeast Brazil. *Braz J Infect Dis* 2007;11:89-95.